Please login to the form below

Not currently logged in
Email:
Password:

Anda

This page shows the latest Anda news and features for those working in and with pharma, biotech and healthcare.

Teva acquires Allergan’s generics operations in $38.8bn deal

Teva acquires Allergan’s generics operations in $38.8bn deal

The Israeli pharmaceutical firm currently has over 400 products awaiting FDA and Abbreviated New Drug Application (ANDA) approval in the US, and expects to launch 1, 500 generics worldwide in 2017. ... Once the transaction has been completed, Anda will

Latest news

  • Piramal sells clinical research arm to Indoco Piramal sells clinical research arm to Indoco

    Apart from reducing cost and ensuring time-bound outcome of studies, the CRO would be a perfect fit to our existing R&D efforts, including facilitation of ANDA/Dossier filings.”.

  • UCB files Vimpat patent claims against 15 companies UCB files Vimpat patent claims against 15 companies

    ANDA) by Aurobindo to market its own version of Vimpat (lacosamide) in the US. ... Other companies have also submitted their own ANDAs, however, encouraged by the prospect of a 180-day exclusivity period for the first generic product to successfully

  • Bayer sues Glenmark over its skin disorder generic Bayer sues Glenmark over its skin disorder generic

    Glenmark filed an Abbreviated New Drug Application (ANDA) to the US FDA for its own version of azeliac acid gel, which is approved for the treatment of inflammatory papules and pustules ... Despite the lawsuit and risk of related penalties, by becoming

  • Watson faces lawsuit over generic contraceptive

    2029. If the court does not rule in favour of Watson, the FDA would be prevented from granting a final approval for Waton's ANDA for 30 months.

  • Par buys Anchen in $410m deal

    California-based Anchen has five commercialised products, 27 abbreviated new drug applications (ANDAs) on file with the US Food and Drugs Administration (FDA), five of which are believed to be

More from news
Approximately 1 fully matching, plus 45 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    acquisition assets. 652. Teva and Allergan/ Impax Laboratories. 15 marketed generics, an approved generic drug and a pipeline generic drug; inc return to Impax of rights to its pending ANDA for ... 8 generic drugs - filed ANDAs pending approval and an

  • Pharma deals in July 2015 Pharma deals in July 2015

    66 ANDA filings and a pipeline of over 65 products.

  • Pharma deals during April 2014 Pharma deals during April 2014

    products including 629 ANDAs.

  • Deal Watch table for August 2013 Deal Watch table for August 2013

    33. Pernix Therapeutics / Breckenridge Pharma. Acquisition. 11 Abbreviated New Drug Applications (ANDAs), certain ANDAs in various stages of development, 7 marketed products.

  • Pharma deals during August 2013 Pharma deals during August 2013

    In its deal with Pernix Therapeutics, Breckenridge Pharmaceutical adds further generic assets including 11+ ANDAs and 7 previously marketed products, covering solid oral products and unique dosage forms, to its already

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics